-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hub-and-spoke (or Portfolio Model): One of the models in the US pharmaceutical market over the past few yea.
It is an option to make assets that big pharmaceutical companies are interested .
hub and spoke R&D model
Such as Cullinan Oncology (NASDAQ:CGEM), BridgeBio Pharma (NASDAQ:BBIO), Roivant Sciences (NASDAQ:ROIV), Fortress Biotech (NASDAQ:FBIO), Centessa (NASDAQ:CNTA), PureTech Health (NASDAQ:PRTC), Gossamer Bio (NASDAQ:GOSS), unlisted Nimbus Therapeutics, ElevateBio, and others follow a similar model, albeit not identical.
A few recent deals worth mentioning:
On May 12, 2022, Cullinan Oncology and Japan's Taiho Pharmaceutical (Taiho Pharmaceutical, a subsidiary of Japan's Otsuka) announced that they have reached a strategic agreement on the new drug Zipalertinib (CLN-081/TAS-6417) for the treatment of EGFR exon 20 insertion mutations In cooperation, Dapeng will acquire Cullinan Pearl, a subsidiary of Cullinan Oncolo.
Zipalertinib compound patent: WO-2015025936
In addition, Cullinan Oncology reserves the option to jointly develop this product with Dapeng's US subsidiary, and if the product is approved in the United States, it will receive an agreed proportion of sales profits (currently split profit.
,
Pharnex Cloud Data,Cloud Data,Currently, Zai Lab owns the rights and interests of this product in Greater China (including Mainland China, Hong Kong, Macau and Taiwa.
In January 2022, CLN-081 was granted Breakthrough Therapy Designation (BTD) by the US F.
On May 12, 2022, BridgeBio announced an exclusive license agreement with BMS to develop and commercialize a new drug, BBP-398 (IACS-13909), a SHP2 inhibit.
BBP-398 Compound Structure
Under the agreement, BridgeBio will remain responsible for the ongoing Phase I monotherapy and combination therapy trials of BBP-39 BMS will be responsible for and fund all other development and commercial activiti.
Source: Yaorong Cloud Data
BBP-398 was originally developed by MD Anderson Cancer Center (University of Texas Anderson Cancer Center), and Navire Pharmaceuticals, a subsidiary of BridgeBio, acquired its global righ.
Due to the complexity of new drug development and the diversity of the competitive environment , an open and selective cooperative development model is more conducive to the advancement of new dru.
The complexity of new drug development and the diversity of the competitive environment
This article is only used to provide scientific information to medical and health professionals and does not represent the platform's position
This article is only used to provide scientific information to medical and health professionals and does not represent the platform's positionrefer to:
refer to:NMPA/CDE;
NMPA/CDE;Yaorong Cloud Data,Cloud Data,FDA/EMA/PMDA;
FDA/EMA/PMDA;Public disclosure of relevant companies;
Public disclosure of relevant companies;https://bridgeb.
https://bridgeb.
and so .
